AbbVie (ABBV) Tops Q4 EPS by 6c, Offers FY Guidance

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.92, $0.06 better than the analyst estimate of $2.86. Revenue for the quarter came in at $13.86 billion versus the consensus estimate of $13.73 billion.

GUIDANCE:

AbbVie sees FY2021 EPS of $12.32-$12.52, versus the consensus of $12.18.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• JinkoSolar (JKS) Misses Q4 EPS by 25c, Revenue Beats, Offers Guidance
• Scotts Miracle-Gro (SMG) Provides Update to Full-Year Financial Guidance; Outlines Strategic Priorities During Investor Day Event
• UPDATE: Mizuho Securities Starts Ameren Corp (AEE) at Neutral (correction)